Trying to save vaccines: Govt panel on delaying shots to Covid survivors

Narendra Kumar Arora, head of the govt's National Technical Advisory Group on Immunisation, said that given the vaccine shortage in India, the focus should have been on immunising the most at risk

Vaccines
Photo: Bloomberg
Reuters
2 min read Last Updated : May 23 2021 | 8:25 PM IST
India is trying to save scarce Covid-19 vaccines by delaying shots for those who have recovered from the disease, the head of a government panel said, adding the campaign should not have been opened to all adults before covering the most vulnerable.

Under fire for his handling of the world's worst rise in coronavirus infections, Prime Minister Narendra Modi made all adults eligible for vaccination from May 1.

Vaccine shortages have now forced many regions, including the capital New Delhi, to again prioritise those aged above 45.

The federal government on Wednesday said patients should go for their vaccination three months after recovery, compared with the earlier recommendation of about one month. It did not give a reason.

"It's been done to save vaccine doses," Narendra Kumar Arora, head of the government's National Technical Advisory Group on Immunisation, told Reuters on Friday. "We discussed delaying it by three months, six months or nine months, but finally we said 'we can manage it with three months, let's do three months for now'".

Arora said that given the vaccine shortage in India, the focus should have been on immunising the most at risk.

"Our group prioritised those aged 45 or more," he said. "Because 75 per cent of the mortality and morbidity is in that age group."

The Ministry of Health and Family Welfare said on April 19 that the decision to include all adults in the immunisation campaign was taken in a meeting chaired by Modi.

The ministry and Modi's office did not respond to a request for comment.

India has administered about 192 million doses, the most after China and the United States, but given the necessary two-doses to only about 3% of its 1.35 billion people.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

Next Story